Avacopan and ADVOCATE Trial
Presenter: Peter A. Merkel, MD, MPH
Chief, Division of Rheumatology, Professor of Medicine
Professor of Epidemiology in Biostatistics and Epidemiology, PENN Medicine
Click here to access the webinar.
The purpose of the ADVOCATE Trial is to learn if avacopan (previously called CCX168) can provide benefits to patients by being safe and effective in improving vasculitis disease activity, kidney function, and/or quality of life. Avacopan is being studied for ANCA vasculitis. For people who suffer from vasculitis who may want to participate in the ADVOCATE Trial, more information can be found on the ADVOCATE website.
In this webinar, Dr. Peter Merkel, principal investigator for the ADVOCATE trial, explains the science behind avacopan and the role of neutrophils in ANCA vasculitis.